Summary
53.76 -0.65(-1.19%)06/17/2024
Arcellx, Inc. Common Stock (ACLX)
Arcellx, Inc. Common Stock (ACLX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.19 | -5.60 | -15.81 | -22.97 | 9.29 | 6.07 | 0.00 | 420.84 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 53.76 | |
| Open | 54.37 | |
| High | 54.69 | |
| Low | 53.53 | |
| Volume | 482,948 | |
| Change | -0.65 | |
| Change % | -1.19 | |
| Avg Volume (20 Days) | 445,432 | |
| Volume/Avg Volume (20 Days) Ratio | 1.08 | |
| 52 Week Range | 30.78 - 75.10 | |
| Price vs 52 Week High | -28.42% | |
| Price vs 52 Week Low | 74.66% | |
| Range | -4.00 | |
| Gap Up/Down | -1.67 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,889 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
05/27 12:32 EST - investorplace.com
7 Biotech Stocks to Put on Your Breakthrough Radar
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
7 Biotech Stocks to Put on Your Breakthrough Radar
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
05/09 18:10 EST - zacks.com
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago.
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago.
05/09 16:05 EST - businesswire.com
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
05/09 16:05 EST - businesswire.com
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
05/09 06:49 EST - investorplace.com
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
04/04 16:00 EST - businesswire.com
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Inv.
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Inv.
04/04 09:41 EST - zacks.com
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
03/20 16:00 EST - businesswire.com
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in t.
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in t.
02/29 16:00 EST - prnewswire.com
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
02/28 20:31 EST - zacks.com
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.
02/28 16:00 EST - prnewswire.com
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.
02/15 11:57 EST - investorplace.com
The 3 Biotech Stocks That Could Make Your February Unforgettable
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
The 3 Biotech Stocks That Could Make Your February Unforgettable
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
01/30 05:13 EST - seekingalpha.com
Arcellx: Navigating The CAR T-Cell Revolution
Arcellx: Navigating The CAR T-Cell Revolution
Arcellx: Navigating The CAR T-Cell Revolution
Arcellx: Navigating The CAR T-Cell Revolution
01/16 13:51 EST - investorplace.com
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
12/15 17:04 EST - investorplace.com
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
12/08 16:00 EST - prnewswire.com
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median progression free survival by Kaplan-Meier is 28 months -- -- Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT -- -- Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median progression free survival by Kaplan-Meier is 28 months -- -- Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT -- -- Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.
11/30 21:37 EST - investorplace.com
3 Biotech Stocks That Could Be Multibaggers in the Making
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
3 Biotech Stocks That Could Be Multibaggers in the Making
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
11/16 11:16 EST - zacks.com
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
11/15 13:44 EST - seekingalpha.com
Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market
Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the previous update, and good safety. The partnership with Gilead Sciences provides a cash infusion and de-risks CART-ddBCMA's manufacturing process.
Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market
Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the previous update, and good safety. The partnership with Gilead Sciences provides a cash infusion and de-risks CART-ddBCMA's manufacturing process.
11/15 11:03 EST - proactiveinvestors.com
Arcellx stock climbs on Gilead investment
Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration.   Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.
Arcellx stock climbs on Gilead investment
Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration.   Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.